Sudeep Pharma IPO is a book-built public issue aimed at raising ₹895.00 crore. The issue consists of a fresh issue of 16.02 lakh equity shares aggregating to ₹95.00 crore, and an offer for sale of 134.90 lakh equity shares amounting to ₹800.00 crore. The IPO bidding window opened on November 21, 2025, and closed on November 25, 2025. The allotment is scheduled to be finalised on November 26, 2025, with the listing set for November 28, 2025, on BSE and NSE.
The IPO was priced in the range of ₹563-₹593 per share, with a lot size of 25 shares. At the close of bidding, the public issue received bids for 99,00,90,700 shares against 1,05,64,927 shares available, resulting in an overall subscription of 93.71 times. The QIB segment led the response with a subscription of 213.08 times, followed by NIIs at 116.72 times. Retail investors subscribed 15.65 times their portion.
Sudeep Pharma’s ₹895.00 crore IPO, priced at ₹563-₹593 per share, recorded an overall subscription of 93.71 times. The issue comprises a fresh issue of 16.02 lakh shares (₹95.00 crore) and an offer for sale of 134.90 lakh shares (₹800.00 crore). The IPO was open for bidding from November 21 to November 25, 2025, and the allotment will be announced on November 26, 2025.
Retail investors bid 15.65 times, while the NII segment subscribed 116.72 times. The company will list its shares on November 28, 2025.
The table below breaks down the Sudeep Pharma share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| QIB Shares Offered | 75,46,376 (50.00%) |
| − Anchor Investor Shares Offered | 45,27,823 (30.00%) |
| − QIB (Ex. Anchor) Shares Offered | 30,18,553 (20.00%) |
| NII (HNI) Shares Offered | 22,63,912 (15.00%) |
| − bNII > ₹10L | 15,09,275 (10.00%) |
| − sNII < ₹10L | 7,54,637 (5.00%) |
| Retail Shares Offered | 52,82,462 (35.00%) |
| Total Shares Offered | 1,50,92,750 (100.00%) |
Data Source: NSE
| Category | Subscription (times) |
| Qualified Institutional Buyers (QIB) | 213.08 |
| Non-Institutional Investors (NII) | 116.72 |
| Retail Individual Investors (RII) | 15.65 |
| Total | 93.71 |
Note: The subscription details are as of November 25, 2025
Sudeep Pharma Limited, incorporated in 1989, is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients with a global footprint. The company supplies its products to more than 100 countries, serving customers across the pharmaceutical, food, and nutrition sectors. Its portfolio includes over 200 products, highlighting its broad industry presence and capability to cater to diverse formulation requirements.
The company operates six manufacturing facilities with a combined capacity of 50,000 MT, producing a wide range of mineral-based excipients, including calcium, magnesium, zinc, sodium, potassium, and iron salts. These facilities are regulatory compliant and equipped with robust quality frameworks, enabling consistent output for both domestic and international clients. Its R&D centres and in-house pilot-scale capabilities support continued innovation, particularly in mineral salts and speciality excipients.
Sudeep Pharma’s competitive strengths include its market leadership in a high-barrier industry, a well-diversified and long-standing global customer base, and a strong manufacturing and research infrastructure. Its strategic positioning in excipients, speciality ingredients, and triturates allows it to cater to niche applications that command high regulatory standards and performance requirements.
As of December 31, 2024, the company employed 704 permanent staff, reflecting the scale of its operations. Its growth has been supported by continuous investment in technology, manufacturing efficiency, and product development, strengthening its role as a preferred supplier to marquee clients worldwide.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Nov 25, 2025, 6:21 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
